摘要
血栓栓塞性疾病常见于恶性肿瘤患者,已成为其重要致死原因。抗凝药物是治疗血栓栓塞性疾病的基石,应用于肿瘤患者较普通人群具有许多特殊之处,常给临床医生带来困惑。近年来,相继有基于肿瘤人群的血栓防治研究见诸报道,亦有部分临床指南和专家共识对肿瘤患者血栓栓塞性疾病的治疗进行指导。结合现有文献,对抗凝药物在肿瘤幸存者中的应用进展进行综述,以期为临床医生提供参考。
Thromboembolic disease is common in patients with malignant tumor and has become one of the leading causes of death. Anticoagulant is the most essential medicine for the treatment of thromboembolic disease, but its application in cancer patients is very different from that in non-cancer patients, bringing a lot of confusions to clinicians. In recent years, some researches on the prevention and treatment of thromboembolism in cancer survivors have been reported. Meanwhile, several guidelines and expert consensus documents have been available as guidance for the treatment of thromboembolism in cancer patients. Based on the currently available literature, advances in the application of anticoagulants in cancer survivors were reviewed in this paper to provide reference for clinicians.
作者
夏云龙
吕海辰
XIA Yunlong;LYU Haichen(Department of Cardiology,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,China)
出处
《药学进展》
CAS
2018年第7期500-505,共6页
Progress in Pharmaceutical Sciences
基金
国家自然科学基金(No.81570313
No.81700245)
